biotech
Biotech M&A Heats Up: Cosette’s $430M Mayne Pharma Acquisition and Industry-Wide Stock Buybacks
Biotech acquisitions, pharmaceutical mergers, stock repurchase programs, women’s health, dermatology, market consolidation
Sionna Therapeutics Raises $191M in Upsized IPO, Aardvark Therapeutics Aims for $100M Listing
Biotech IPOs, Sionna Therapeutics, Aardvark Therapeutics, Cystic Fibrosis, Metabolic Diseases, NASDAQ, Obesity Treatment
Metsera and Maze Therapeutics Raise $415 Million in Successful Biotech IPOs
Biotech IPOs, Metsera, Maze Therapeutics, obesity treatment, kidney disease, NASDAQ listings, pharmaceutical funding
Biotech IPO Momentum: Maze and Metsera’s Dual Debut Signals Renewed Market Optimism
Biotech IPOs, Maze Therapeutics, Metsera, obesity treatment, precision medicine, market optimism, 2025 IPO trends
New year starts with a bang as trio of venture financings brings in $382M
Venture capital, Biotech funding, Megarounds, Tenvie Therapeutics, Private financing, Life sciences investments
Delaware Court Ruling Paves Way for Aurion Biotech IPO, Alcon to Appeal Decision
Aurion Biotech, Alcon Research, IPO, Delaware Court of Chancery, reverse stock split, voting proxy, Series C consent rights
Aurion Biotech Presses On with IPO Plans Amid Legal Dispute with Investor Alcon
Aurion Biotech, IPO, legal dispute, Alcon, cell therapy, biotech investment
Biotech IPOs Kick Off 2025: Ascentage Pharma Raises $126M, Aardvark Therapeutics Files for IPO
Biotech IPOs, Ascentage Pharma, Aardvark Therapeutics, Cancer Treatment, Obesity Treatment, Pharmaceutical Industry
Biotech IPO Market Expected to Rebound in 2025 with Increased Investor Optimism
Biotech IPOs, 2025 Outlook, Investor Optimism, Therapeutic Innovation, Strategic Differentiation
Key Presentations at JPM25: AbbVie, UCB, WuXi Biologics Highlight Industry Trends
JPM25, J.P. Morgan Healthcare Conference, AbbVie, UCB, WuXi Biologics, Biotech Trends, Healthcare Innovation